TD Cowen Maintains Buy on Medpace Hldgs, Lowers Price Target to $434
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Charles Rhyee maintains a Buy rating on Medpace Holdings (NASDAQ:MEDP) but lowers the price target from $452 to $434.

July 24, 2024 | 2:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
TD Cowen analyst Charles Rhyee maintains a Buy rating on Medpace Holdings but lowers the price target from $452 to $434.
The maintained Buy rating suggests continued confidence in Medpace Holdings' performance, but the lowered price target indicates a slightly less optimistic outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100